نتایج جستجو برای: روغن سویای اپوکسی دارشده eso

تعداد نتایج: 12646  

پایان نامه :وزارت علوم، تحقیقات و فناوری - دانشگاه علامه طباطبایی - دانشکده اقتصاد 1391

موضوع و طرح مسئله (اهمیت موضوع و هدف): بررسی میزان مصرف روغن نباتی درکشور نشاندهنده افزایش قابل توجه سرانه مصرف این ماده غذایی است به طوری که مصرف سرانه آن از مقدار 5/2 کیلوگرم در اوایل دهه 1340 و 7/4 کیلوگرم دراوایل دهه 1350 به 16 کیلوگرم دراوایل دهه 1380 (معاونت زراعت وزارت جهاد کشاورزی،1382) رسیده است. درسال 1388 این عدد به میزان تقریبی 20 کیلوگرم به ازای هرنفررسیده است (ivoi, 2010). بدین ت...

ژورنال: علوم و فناوری رنگ 2012

دو سری آمیدوآمین‌های مشتق پلی آمین خطی تری‌اتیلن تتراآمین و روغن کرچک ساخته و به عنوان عامل پخت برای پخت پوشش‌های اپوکسی به کار رفت. بررسی خواص مکانیکی پوشش‌های حاصل حاکی از آن است که پوشش‌های به دست آمده علاوه بر انعطاف‌پذیری بسیار مناسب، چسبندگی بالاتری را نسبت به پوشش‌های پخت شده با پلی‌آمین مشابه از خود نشان می‌دهند. همچنین افزایش میزان روغن کرچک سبب افزایش بیشتر انعطاف و چسبندگی پوشش به سط...

Journal: :Cancer research 2003
Kunle Odunsi Achim A Jungbluth Elisabeth Stockert Feng Qian Sacha Gnjatic Jonathan Tammela Marilyn Intengan Amy Beck Bernadette Keitz Darren Santiago Barbara Williamson Matthew J Scanlan Gerd Ritter Yao-Tseng Chen Deborah Driscoll Ashwani Sood Shashikant Lele Lloyd J Old

Cancer-testis (CT) antigens are expressed in a variety of cancers, but not in normal adult tissues, except for germ cells of the testis, and hence appear to be ideal targets for immunotherapy. In an effort to examine the potential of NY-ESO-1 and LAGE-1 CT antigens for immunotherapy in epithelial ovarian cancer (EOC), we examined the expression of these antigens by reverse transcription-PCR (RT...

2016
Elizabeth Shurell Maria E. Vergara-Lluri Yunfeng Li Joseph G. Crompton Arun Singh Nicholas Bernthal Hong Wu Fritz C. Eilber Sarah M. Dry

BACKGROUND Immunotherapy targeting cancer-testis antigen NY-ESO-1 shows promise for tumors with poor response to chemoradiation. Malignant peripheral nerve sheath tumors (MPNSTs) and liposarcomas (LPS) are chemoresistant and have few effective treatment options. Materials Methods: Using a comprehensive tissue microarray (TMA) of both benign and malignant tumors in primary, recurrent, and metast...

2003
Kunle Odunsi Achim A. Jungbluth Elisabeth Stockert Feng Qian Sacha Gnjatic Jonathan Tammela Marilyn Intengan Amy Beck Bernadette Keitz Darren Santiago Barbara Williamson Matthew J. Scanlan Gerd Ritter Yao-Tseng Chen Deborah Driscoll Ashwani Sood Shashikant Lele Lloyd J. Old

Cancer-testis (CT) antigens are expressed in a variety of cancers, but not in normal adult tissues, except for germ cells of the testis, and hence appear to be ideal targets for immunotherapy. In an effort to examine the potential of NY-ESO-1 and LAGE-1 CT antigens for immunotherapy in epithelial ovarian cancer (EOC), we examined the expression of these antigens by reverse transcription-PCR (RT...

Journal: :Cancer research 2000
H M Zarour W J Storkus V Brusic E Williams J M Kirkwood

The NY-ESO-1 gene is expressed by a range of human tumors and encodes HLA-A2-restricted melanoma peptides recognized by CD8+ CTLs. Here we report that the NY-ESO-1 gene also encodes two overlapping, but non-cross-reactive, HLA-DRB1*0401-presented peptides that are recognized by CD4+ T cells. The NY-ESO-1(119-143) peptide was able to induce specific CD4+ T cells in vitro from both an HLA-DRB1*04...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 2010
Junko Matsuzaki Sacha Gnjatic Paulette Mhawech-Fauceglia Amy Beck Austin Miller Takemasa Tsuji Cheryl Eppolito Feng Qian Shashikant Lele Protul Shrikant Lloyd J Old Kunle Odunsi

NY-ESO-1 is a "cancer-testis" antigen frequently expressed in epithelial ovarian cancer (EOC) and is among the most immunogenic tumor antigens defined to date. In an effort to understand in vivo tolerance mechanisms, we assessed the phenotype and function of NY-ESO-1-specific CD8(+) T cells derived from peripheral blood lymphocytes (PBLs), tumor-infiltrating lymphocytes (TILs), and tumor-associ...

Journal: :Cancer immunology research 2014
Kunle Odunsi Junko Matsuzaki Smitha R James Paulette Mhawech-Fauceglia Takemasa Tsuji Austin Miller Wa Zhang Stacey N Akers Elizabeth A Griffiths Anthony Miliotto Amy Beck Carl A Batt Gerd Ritter Shashikant Lele Sacha Gnjatic Adam R Karpf

The cancer-testis/cancer-germline antigen NY-ESO-1 is a vaccine target in epithelial ovarian cancer (EOC), but its limited expression is a barrier to vaccine efficacy. As NY-ESO-1 is regulated by DNA methylation, we hypothesized that DNA methyltransferase (DNMT) inhibitors may augment NY-ESO-1 vaccine therapy. In agreement, global DNA hypomethylation in EOC was associated with the presence of c...

2015
Agnes S. Klar Jakka Gopinadh Sascha Kleber Andreas Wadle Christoph Renner Francesco Dieli

BACKGROUND NY-ESO-1 belongs to the cancer/testis antigen (CTA) family and represents an attractive target for cancer immunotherapy. Its expression is induced in a variety of solid tumors via DNA demethylation of the promoter of CpG islands. However, NY-ESO-1 expression is usually very low or absent in some tumors such as breast cancer or multiple myeloma. Therefore, we established an optimized ...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 2007
Kunle Odunsi Feng Qian Junko Matsuzaki Paulette Mhawech-Fauceglia Christopher Andrews Eric W Hoffman Linda Pan Gerd Ritter Jeannine Villella Bridget Thomas Kerry Rodabaugh Shashikant Lele Protul Shrikant Lloyd J Old Sacha Gnjatic

NY-ESO-1 is a "cancer-testis" antigen expressed in epithelial ovarian cancer (EOC) and is among the most immunogenic tumor antigens defined to date. The NY-ESO-1 peptide epitope, ESO(157-170), is recognized by HLA-DP4-restricted CD4+ T cells and HLA-A2- and A24-restricted CD8+ T cells. To test whether providing cognate helper CD4+ T cells would enhance the antitumor immune response, we conducte...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید